Advertisement

 

 

Increased expression of Fibrinogen-Like Protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma.

Increased expression of Fibrinogen-Like Protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma.
Author Information (click to view)

Tang M, Cao X, Li P, Zhang K, Li Y, Zheng QY, Li GQ, Chen J, Xu GL, Zhang KQ,


Tang M, Cao X, Li P, Zhang K, Li Y, Zheng QY, Li GQ, Chen J, Xu GL, Zhang KQ, (click to view)

Tang M, Cao X, Li P, Zhang K, Li Y, Zheng QY, Li GQ, Chen J, Xu GL, Zhang KQ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Scientific reports 2017 10 047(1) 12676 doi 10.1038/s41598-017-13149-x
Abstract

Fibrinogen-like protein 2 (FGL2) is highly expressed in various tumour tissues and plays a vital role in tumour initiation and progression. This study evaluated the clinical significance of FGL2 in patients with clear cell renal cell carcinoma (ccRCC). FGL2 expression in fresh and 170 archived paraffin-embedded ccRCC tissues was measured by quantitative RT-PCR, western blotting, and immunohistochemitry. FGL2 expression was significantly upregulated in ccRCC. Statistical analyses by using Kaplan-Meier method showed that high FGL2 expression was associated with poor overall survival (OS) and recurrence-free survival (RFS) of patients with ccRCC. Multivariate analyses indicated that FGL2 was as an independent prognostic factor of survivaland that tumoural FGL2 levels could significantly predict the prognosis of patients with early-stage ccRCC. Nomogram systems, which integrated FGL2 expression and other clinical parameters, were established and were found to be better than TNM staging in predicting the OS and RFS of patients with ccRCC. FGL2 silencing led to a significant reduction in cells viability and increase in cells apoptosis, accompanied with a reduced ERK1/2 and p38 MAPK activation, in ccRCC cells. Thus, our results suggest that high FGL2 expression is a novel, independent, and an adverse prognostic factor of clinical outcomes in patients with ccRCC.

Submit a Comment

Your email address will not be published. Required fields are marked *

one × one =

[ HIDE/SHOW ]